Positive CHMP Opinion Received for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting

Ahsan Arozullah, MD, MPH, Senior Vice President and Head of Oncology Development, Astellas, “Men with nmHSPC with high-risk biochemical recurrence are very likely to experience disease progression. With approximately 9 out of 10 of these men developing metastatic disease, the need for new and effective treatment options is critical. Today’s positive opinion from the Committee is an important step forward for providing an additional treatment option for these patients and complements the existing efficacy and safety data supporting the use of XTANDI across the prostate cancer disease continuum. We look forward to XTANDI being potentially the first and only androgen receptor signaling inhibitor approved for this patient population in the European Union.”